27.19
price up icon0.59%   0.16
after-market Handel nachbörslich: 26.91 -0.28 -1.03%
loading

Alkermes Plc Aktie (ALKS) Neueste Nachrichten

pulisher
09:54 AM

Goldman Sachs Initiates Alkermes (ALKS) with a Buy Rating - MSN

09:54 AM
pulisher
09:38 AM

What analysts say about Alkermes plc stockHigh-yield portfolio picks - Autocar Professional

09:38 AM
pulisher
09:34 AM

Alkermes plc (NASDAQ:ALKS) Launches Phase II Trial of ALKS 2680 for Idiopathic Hypersomnia - MSN

09:34 AM
pulisher
05:48 AM

Alkermes plc Stock Analysis and ForecastSuperior investment outcomes - jammulinksnews.com

05:48 AM
pulisher
03:00 AM

What drives Alkermes plc stock priceConsistently exceptional gains - Autocar Professional

03:00 AM
pulisher
Jul 22, 2025

Is Alkermes plc a good long term investmentFree Wealth Planning Blueprint - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

Alkermes (ALKS) Expected to Beat Earnings Estimates: Should You Buy? - Yahoo Finance

Jul 22, 2025
pulisher
Jul 22, 2025

ALKS Down Despite Positive Top-Line Data From Narcolepsy Study - Yahoo Finance

Jul 22, 2025
pulisher
Jul 21, 2025

Alkermes Announces Positive Phase 2 Study Results - TipRanks

Jul 21, 2025
pulisher
Jul 21, 2025

Alkermes To Advance Alixorexton After Positive Phase II Narcolepsy Results - insights.citeline.com

Jul 21, 2025
pulisher
Jul 21, 2025

Jefferies Raises Target for Alkermes (ALKS) Following Promising Drug Data | ALKS Stock News - GuruFocus

Jul 21, 2025
pulisher
Jul 21, 2025

Alkermes Offers The Next Proof Point For Its Narcolepsy Approach. Stock Dives. - inkl

Jul 21, 2025
pulisher
Jul 21, 2025

Alkermes Oral Drug Helps Patients Stay Awake In Mid-Stage Sleep Disorder Study - inkl

Jul 21, 2025
pulisher
Jul 21, 2025

Alkermes narcolepsy drug headed for late-stage testing - BioPharma Dive

Jul 21, 2025
pulisher
Jul 21, 2025

Needham & Company LLC Reaffirms Buy Rating for Alkermes (NASDAQ:ALKS) - MarketBeat

Jul 21, 2025
pulisher
Jul 21, 2025

Alkermes stock rating reiterated as Buy by Stifel after positive narcolepsy data - Investing.com UK

Jul 21, 2025
pulisher
Jul 21, 2025

Alkermes Vibrance-1 Phase 2 Study Of Alixorexton In Narcolepsy Type 1 Meets Primary Goal - Nasdaq

Jul 21, 2025
pulisher
Jul 21, 2025

Alkermes announces positive topline results from Vibrance-1 Phase 2 study - MarketScreener

Jul 21, 2025
pulisher
Jul 21, 2025

Alkermes narcolepsy drug shows positive results in phase 2 trial By Investing.com - Investing.com UK

Jul 21, 2025
pulisher
Jul 21, 2025

Alkermes Announces Positive Topline Results From Vibrance-1 Phase 2 Study of Once-Daily Alixorexton in Patients With Narcolepsy Type 1 - PR Newswire

Jul 21, 2025
pulisher
Jul 20, 2025

Is Alkermes Plc's (NASDAQ:ALKS) Latest Stock Performance Being Led By Its Strong Fundamentals? - 富途牛牛

Jul 20, 2025
pulisher
Jul 19, 2025

10 Most Undervalued Pharma Stocks To Buy Now - Insider Monkey

Jul 19, 2025
pulisher
Jul 17, 2025

BlackRock increases stake in Alkermes to 17.05% By Investing.com - Investing.com India

Jul 17, 2025
pulisher
Jul 17, 2025

BlackRock increases stake in Alkermes to 17.05% - Investing.com

Jul 17, 2025
pulisher
Jul 15, 2025

Alkermes to Release Q2 Financial Results on July 29, 2025 - AInvest

Jul 15, 2025
pulisher
Jul 15, 2025

Alkermes to Report Second Quarter Financial Results on July 29, 2025 - MarketScreener

Jul 15, 2025
pulisher
Jul 15, 2025

Expert Outlook: Alkermes Through The Eyes Of 6 Analysts - Benzinga

Jul 15, 2025
pulisher
Jul 15, 2025

Goldman Sachs Initiates Coverage on Alkermes (ALKS) with a Buy R - GuruFocus

Jul 15, 2025
pulisher
Jul 14, 2025

How Much Upside is Left in Alkermes (ALKS)? Wall Street Analysts Think 33.19% - Yahoo Finance

Jul 14, 2025
pulisher
Jul 14, 2025

(ALKS) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com

Jul 14, 2025
pulisher
Jul 08, 2025

Alkermes (NASDAQ:ALKS) shareholders have earned a 9.3% CAGR over the last five years - simplywall.st

Jul 08, 2025
pulisher
Jul 03, 2025

INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Alkermes plc of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 22, 2018ALKS - ACCESS Newswire

Jul 03, 2025
pulisher
Jul 03, 2025

Zacks Industry Outlook Highlights Exelixis, Verona Pharma, Alkermes, Kiniska Pharmaceuticals and Immunocore - Yahoo Finance

Jul 03, 2025
pulisher
Jun 30, 2025

Alkermes plc(NasdaqGS: ALKS) added to Russell 2500 Value Index - MarketScreener

Jun 30, 2025
pulisher
Jun 26, 2025

Alkermes spinoff Mural plunges on plans to halt ovarian cancer trial - MSN

Jun 26, 2025
pulisher
Jun 23, 2025

(ALKS) On The My Stocks Page - news.stocktradersdaily.com

Jun 23, 2025
pulisher
Jun 18, 2025

Alkermes Gains Momentum With Promising Narcolepsy Drug - Finimize

Jun 18, 2025
$73.31
price up icon 1.34%
$15.02
price up icon 0.60%
$9.37
price up icon 1.41%
drug_manufacturers_specialty_generic RDY
$14.60
price up icon 1.32%
$133.66
price up icon 0.69%
$305.61
price up icon 2.59%
Kapitalisierung:     |  Volumen (24h):